A molecular-diversity-oriented approach for the preparation of bicyclic sp 2 -iminosugar glycomimetics related to nojirimycin and galactonojirimycin is reported. The synthetic strategy takes advantage of the ability of endocyclic pseudoamide-type atoms in five-membered cyclic iso(thio)ureas and guanidines to undergo intramolecular nucleophilic addition to the masked carbonyl group of monosaccharides. The stereochemistry of the resulting hemiaminal stereocenter is governed by the anomeric effect, with a large preference for the axial (pseudo-a) orientation. A library of compounds differing in the stereochemistry at the position equivalent to C-4 in monosaccharides (D-gluco and D-galacto), the heterocyclic core (cyclic isourea, isothiourea or guanidine) and the nature of the exocyclic nitrogen substituent (apolar, polar, linear or branched) has been thus prepared and the glycosidase inhibitory activity evaluated against commercial glycosidases. Compounds bearing lipophilic substituents behaved as potent and very selective inhibitors of b-glucosidases. They further proved to be good competitive inhibitors of the recombinant human b-glucocerebrosidase (imiglucerase) used in enzyme replacement therapy (ERT) for Gaucher disease. The potential of these compounds as pharmacological chaperones was assessed by measuring their ability to inhibit thermal-induced denaturation of the enzyme in comparison with N-nonyl-1-deoxynojirimycin (NNDNJ). The results indicated that amphiphilic sp 2 -iminosugars within this series are more efficient than NNDNJ at stabilizing b-glucocerebrosidase and have a strong potential in pharmacological chaperone (PC) and ERT-PC combined therapies.
Introduction
Sugar mimics bearing endocyclic nitrogen atoms (iminosugars and azasugars), such as deoxynojirimycin (DNJ) 1 and castanospermine 2, have been shown to behave as potent glycosidase inhibitors (Fig. 1) . Given the broad range of biological and pathological processes in which glycosidases are involved, from the catabolism of sugars to the biosynthesis of the complex oligosaccharide chains in glycoproteins and glycolipids, specific inhibitors of 
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Despite their promise, neither 1 or 2 nor other members of this family of glycomimetics have realized their full clinical potential. This is largely because of a lack of commercially viable syntheses and difficulties in preparing a comprehensive palette of variant structures. Moreover, in most cases the lack of specificity between different isoenzymes represents an important problem for clinical applications. In order to tackle the problems of enzyme selectivity, several years ago we developed a new family of glycomimetics in which the amine-type nitrogen characteristic of iminosugars was replaced by a pseudoamide-type nitrogen atom with high sp 2 -character (sp 2 -iminosugars; e.g. compounds 3 and 4). 6 This structural modification profoundly alters the stereoelectronic properties at the pseudoanomeric region, rendering compounds that are chemically, conformationally and configurationally stable in water solution even when incorporating oxygen (hemiaminals), nitrogen (gem-diamines) or sulfur substituents (aminothioacetals) at the position equivalent to C-1 in monosaccharides. 7 For instance, the pseudoanomeric hydroxyl group in the cyclic carbamate nojirimycin derivative 3 was found exclusively in the axial orientation, as determined by the generalized anomeric effect, matching the configurational pattern of a-glucopyranosides. 8 Accordingly, it behaved as a potent and selective inhibitor of yeast a-glucosidase (K i 2.2 mM), being inactive against several b-glucosidases. Notwithstanding, a dramatic shift in the a/b-glucosidase selectivity was observed for cyclic isourea analogues bearing aliphatic substituents at the exocyclic nitrogen atom, e.g. 5 (K i 1.7 mM against almond b-glucosidase; no inhibition of yeast a-glucosidase) even though they likewise existed in the a-like configuration in water solution. 9 Compound 5 was also a potent and selective inhibitor of human lysosomal b-glucosidase (b-glucocerebrosidase, GlcCerase). Most interestingly, it promoted the correct folding in GlcCerase mutants associated with Gaucher disease and their trafficking to the lysosome, being currently under study as pharmacological chaperone for the treatment of this pathology.
10
X-Ray crystallographic studies showed that isourea 5 is actually present in the b-configuration in the active site of b-glucosidases.
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This enzyme-dependent induced fit process is promoted by the substituent at the imine functionality, which locates in a hydrophobic pocket at the vicinity of the active site of b-glucosidases resulting in a remarkably high favourable entropic contribution to binding.
Interestingly, replacement of the endocyclic oxygen atom by sulfur or nitrogen increased the inhibitory potency for b-glucosidases while preserving the anomeric selectivity (K i 0.76 and 0.42 mM against almond b-glucosidase for isothiourea 6 and guanidine 7, respectively). 12 Inversion of the configuration at the position equivalent to C-4 in monosaccharides, thereby shifting from a hydroxylation pattern of structural complementarity to D-glucose to a D-galactose-type profile, further enhanced the inhibitory potential against b-glucosidases (e.g., K i 0.023 mM against almond b-glucosidase for isothiourea 9 and K i 0.04 mM against bovine liver b-glucosidase for guanidine 10). Actually, compounds 6-10 also showed chaperone activity in Gaucher fibroblasts with several mutations, with isothiourea derivatives 6 and 9 being the most active candidates followed by guanidine 7. Contrary to classical sp 3 -iminosugars such as 1 or the corresponding Nalkyl derivatives, the sp 2 -iminosugars were particularly active for mutations leading to neuronopathic types of the disease. Mutation profiling also evidenced differences in their chaperoning activity that were mutation-dependent.
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The above commented results illustrate how structural modifications in the skeleton and substitution profile of sp 2 -iminosugar glycomimetics can be exploited to finely tune their enzyme inhibition and pharmacological chaperone selectivity and potency even for closely similar mutant enzymes. The implementation of synthetic strategies allowing elaboration of a collection of derivatives for structure-activity relationship (SAR) studies seemed therefore very appealing. Given the promising results obtained with the isothiourea and guanidine-type bicyclic cores both of the Dgluco and D-galacto isosteric series in pharmacological chaperone therapy approaches, a systematic investigation of the effect of a variety of N¢-substituents in their biological activity has now been undertaken.
Results and discussion

Synthesis
In principle, the target bicyclic skeleton containing the isothiourea or guanidine functionality I (X = S or NH) can be obtained by intramolecular furanose→piperidine rearrangement of 2-aminothiazoline or 2-aminoimidazoline pseudo-C-nucleoside precursors (IIa), respectively, after liberating the aldehyde functionality (IIb) of the monosaccharide. For iminothiazolidine derivatives, the key thiazoline synthetic intermediate (II, X = S) can be prepared from vicinal hydroxythiourea precursors III following activation of the primary hydroxyl group for nucleophilic displacement by the thiocarbonyl sulfur atom. This retrosynthetic scheme is particularly appealing for generating molecular diversity in an efficient manner since thioureas can be readily prepared by coupling of isothiocyanates and amines, which generally proceed with total chemoselectivity and high yield in the presence of OH functionalities. 13 The corresponding imidazoline derivatives (II, X = NH) could be obtained from 5,6-(cyclic isothiouronium) salt intermediates IV by nucleophilic displacement of the alkylthio group by amine (Fig. 2) .
For practical reasons, the already reported 5-azido-5-deoxy-1,2-O-isopropylidene-6-O-tetrahydropyranyl-a-D-glucofuranose and 5-azido-5-deoxy-1,2-O-isopropylidene-a-D-galactofuranose 11 14 and 12 15 were chosen as starting materials (Fig. 3) . The corresponding 5-amino-5-deoxy-sugars can be readily generated by catalytic hydrogenation and were used in the subsequent coupling reactions without further purification. For the synthesis of thiourea intermediates III, we first selected n-butyl isothiocyanate (13), 2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl isothiocyanate (14) 16 and phenyl isothiocyanate (15) as representative examples of alkyl, glycosyl and aryl substituted electrophile counterparts, respectively. Since a preliminary screening revealed the superiority of alkyl-bearing amphiphilic sp 2 -iminosugars as b-glucosidase binders, a broader battery of alkyl isothiocyanate building blocks was incorporated, including branched and linear derivatives bearing different chemical functionalities (16) (17) (18) (19) (20) (21) ; Fig. 3 ). The selected isothiocyanate precursors were commercially available (13, 15 and 18) or were obtained in a limited number of steps by isothiocyanation of the corresponding amines. Thus, the glucopyranosyl derivative 14 was prepared from Dglucose as reported in the literature. 16 The branched isothiocyanate 16 was synthesized from [bis(2-aminoethyl)-2-(tertbutoxycarbonylamino)ethyl]amine (22) 17 by N-hexanoylation of the free primary amino groups (→23), subsequent deprotection of the carbamate group (→24) and isothiocyanation of the generated primary amine by treatment with thiophosgene. Compound 17 was obtained in good yield by isothiocyanation of the corresponding amine 25 18 using thiophosgene. The preparation of 4-
(1-adamantylcarboxamido)butyl isothiocyanate (19) was carried out using a two-step process that involved condensation of N-(tertbutoxycarbonyl)butanediamine (26) and adamantane-1-carbonyl chloride (→27) followed by carbamate hydrolysis and isothiocyanation. A similar strategy was followed for the preparation of compound 20, incorporating an oligoethylene segment, from 11-azido-3,6,9-trioxaundecylamine (28) 19 but in this case the azido group in the amine adduct 29 was directly transformed into isothiocyanate by reaction with triphenylphosphine-carbon disulfide. 20 Finally, the azidoalkyl isothiocyanate 21 was obtained from 28 (Scheme 1) following isothiocyanation with thiophosgene. during the subsequent thiazoline ring formation. In the case of the N¢-phenylthioureido derivative concomitant N-acetylation occurred, 21 leading to a 2 : 1 mixture of 32 and 33. This is not detrimental for the overall yield of the reaction sequence as discussed hereinafter. Attempts to activate the primary hydroxyl as leaving group by trifluoromethanesulfonylation (triflation)
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in 30-33 were unsuccessful. Nevertheless, treatment with mesyl chloride and pyridine at low temperature proceeded with spontaneous nucleophilic displacement of the transient mesylate by the vicinal thiocarbonyl sulfur atom to afford the requested 2-aminothiazolines with total selectivity in good yield (60-86%). The thiourea sulfur is reported to react faster than the nitrogen atoms in nucleophilic displacements, which is consistent with the obtained result. 23 In the case of the N¢-butyl and N¢-b-D-glucopyranosyl derivatives the 3-O-acetyl derivatives 34 and 35 were thus characterized, whereas in the case of the of N¢-phenylthioureas 32 and 33 the cyclization product was subjected to subsequent deacetylation to yield the 2-aminothiazoline 36 as the only reaction product (67%). Further removal of the protecting groups afforded the target bicyclic nojirimycin derivatives 37-39 in 70-80% yield.
The synthesis of the 5-N,6-S-(N¢-iminomethylidene)-6-thionojirimycin derivatives 52-57 followed a similar approach, starting from azide 11 as a common intermediate. Protection of the secondary hydroxyl group OH-3 in the thiourea derivatives 40-45 was found to be not necessary since the mesyl-promoted cyclization proceeded with total regioselectivity to give the desired thiazolines 46-51 (Scheme 3). This general synthetic strategy was next applied to the preparation of the bicyclic galactonojirimycin derivatives 62 and 63, the C-4 epimers of compounds 37 and 39 (Scheme 4). 5-Azido-5-deoxy-1,2-O-isopropylidene-b-Dgalactofuranose (12) , available from commercial a-D-galactose, 15 was used as starting material for accessing the corresponding thioureas 58 and 59, which were subjected to cyclization (→60 and 61) and final pyranose→sp 2 -iminosugar rearrangement. 5-Deoxy-5-guanidinosugars can be accessed from the corresponding 5-azido-5-deoxysugars via carbodiimide intermediates; 24 however, their use as precursors of cyclic guanidines via nucleophilic displacement of a vicinal sulfonate ester is not appropriate due to the high basicity and low nucleophilicity of the guanidine functionality. An alternative strategy was thus developed for the preparation of 6-amino-6-deoxy-5,6-di-N¢-(N¢-iminomethylidene)nojirimycin (70, 71) and galactonojirimycin derivatives (72, 73) starting from the 5,6-(cyclic thiourea) intermediates 64 and 65.
10, 12 Transformation of the thioureas into S-methyl isothiouronium salts followed by reaction with n-butylamine or benzylamine afforded the corresponding cyclic guanidines 66-69 in good yields, which were characterized as the corresponding hydrochlorides. Deprotection of the acetal functionality and treatment with sodium hydroxide gave the target sp 2 -iminosugar glycomimetics 70-73, likewise characterized as the corresponding hydrochloride salts (Scheme 5).
The structure and purity of all the prepared compounds were confirmed by spectroscopic and analytical techniques. The 13 C NMR spectra of the 2-aminothiazoline derivatives (34-36, 46-51, 60, 61) showed a characteristic signal at 166.2-161.3 ppm corresponding to the double bonded carbon and a high field shift of the C-6 resonance (37.9-33.3 ppm) with respect to the thiourea precursors (30-33, 40-45, 58 and 59), confirming the replacement of oxygen by sulfur at this position. In the case of the 2-aminoimidazoline derivatives (66-69) a signal at 159.9-155.9 ppm confirmed the presence of the imino functionality. 2 -iminosugars. In the case of compounds with aliphatic substituents, the presence of the b-like anomer in the solution was detected by NMR, but with a large preference (>95%) for the a-like diastereomer.
Evaluation of the glycosidase inhibitory activity
All the new sp 2 -iminosugars synthesised were first tested as inhibitors against a series of commercial glycosidases including a-glucosidase (yeast), b-glucosidase (almonds), b- 25 a-galactosidase (green coffee beans), isomaltase (yeast), and a-L-fucosidase (pig kidney). The corresponding inhibition constants (K i ) are collected in Tables 1 (for bicyclic nojirimycin derivatives) and 2 (for bicyclic galactonojirimycin derivatives). The corresponding data for the previously synthesized derivatives 5-10 have been also included for comparative purposes.
In agreement with previous results on related N-substituted iminomethylydene derivatives, 9 no or weak inhibition of the glycosidases acting on a-glucopyranosides, namely yeast a-glucosidase, isomaltase or amyloglucosidase, was observed in all cases in spite of the matching configuration at the (pseudo)anomeric centre. It must be noted, however, that except compounds 38 and 52 all compounds with D-gluco configurational pattern were weak to moderate inhibitors of pig kidney trehalase, an enzyme known to be strongly inhibited by isourea and isothiourea derivatives ( Table 1) . 26 The isothiourea-type nojirimycin derivatives also inhibited pig kidney a-L-fucosidase in the low micromolar range ( Table 1) . Most interestingly, all the N¢-alkyl-substituted iminothiazolidine derivatives (6, 37, 52-57) behaved as micromolar to nanomolar inhibitors of the b-glucosidases from almonds and bovine liver as well as of naringinase from Penicillium decumbens, an enzyme having b-glucosidase (E.C. 3.2.1.21) and a-L-rhamnosidase (E.C. 3.2.1.40) activities, in spite of the mismatching configuration at the pseudoanomeric centre. Compounds exhibiting strong inhibition for the two first b-glucosidases have been shown previously to be good candidates as pharmacological chaperones for the treatment of Gaucher disease. Therefore, this assay was used to select compounds for further evaluation against human bglucocerebrosidase. The inhibition potency seems to be related to the hydrophobicity of the N¢-substituent. Thus, incorporation of a terminal protonatable amino group (i.e., 53 and 54) resulted in a significant increase in the corresponding K i values (2.5 and 4.4-fold in the case of the bovine liver enzyme) as compared with the parent N¢-alkyl derivative (i.e., 6 and 37). Similarly, compounds 56 and 57, incorporating a triethylene glycol moiety, were one to two orders of magnitude weaker inhibitors than compounds having hydrophobic substituents. This substantially worse inhibition might have its origin in the high desolvation energy of the polyethylene glycol-based arm, an effect that increases with length.
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The mammalian b-glucosidase seems to be more sensitive to modifications at the exocyclic nitrogen substituent of the inhibitor. Thus, the adamantylcarboxamidobutyl derivative 55 was up to 1.7-fold a more potent inhibitor that the N¢-octyl derivative 6 against almond b-glucosidase but 18.4-fold weaker against bovine liver b-glucosidase. Replacement of the octyl chain (i.e., in 7) into butyl and phenyl (i.e., in 70 and 71, respectively) was also strongly detrimental for the inhibitory activity in the cyclic guanidine-type bicyclic nojirimycin series.
Comparison of the inhibition data for D-gluco (Table 1 ) and D-galacto-configured compounds (Table 2 ) indicated that the later tend to be more potent inhibitors against the b-glucosidases from almonds and bovine liver (i.e., 7, 37, 39, and 70 versus 10, 62, 63, and 72, respectively). It is known that iminosugars with hydroxylation patterns of stereochemical complementarity to Dgalactose are often moderate to good inhibitors of family 1 bglucosidases, 28 which are not very selective enzymes regarding the configuration at C-4 in the substrates.
Compounds 5-10, 37, 52, 55-57, 62, 70, and 71were further evaluated as inhibitors of the recombinant GlcCerase (imiglucerase, Cerezyme R from Genzyme) ( Tables 1 and 2 ). Activity data reflect a clear dependence of GlcCerase inhibition on the nature of the exocyclic substituent. In agreement with the correlation between amphiphilicity and inhibitory activity observed in other glycomimetic families, 29 the inhibitory potency decreased when decreasing the hydrophobicity of the N¢-substituent, irrespective of the nature of the endocyclic heteroatom at the five-membered ring. Thus, the presence of polar groups (e.g. 56 and 57 versus 55) or shortening the aliphatic alkyl chain (i.e. 37, 62 and 70 versus 6, 9 and 7, respectively) involved a significant diminution of the inhibitory activity.
Evaluation of the potential for chaperoning activity
Enzyme stabilization under thermal denaturation conditions was used as an indication of the potential of the target compounds to behave as pharmacological chaperones. 30 Recovery of GlcCerase activity after heating at 48
• C was measured in the absence and in the presence of increasing concentrations (50, 100 and 150 mM) of the selected sp 2 -iminosugars at different incubation times (Fig. 4) . Untreated GlcCerase lost most of its activity after 1 h of denaturation under these conditions (less than 10% activity remained). Compounds 5, 6, 7, 9, 52, and 55 exhibited a remarkable stabilization effect, whereas compounds 8, 37, 62, 10, 56, 57, 71 did not protect the enzyme against thermal inactivation. Accordingly, this protective effect increased gradually with the lipophilicity.
The stabilization activity of the sp 2 -iminosugars was challenged against that of N-(n-nonyl)deoxynojirimycin (NNDNJ), 29 an amphiphilic iminosugar currently under investigation as pharmacological chaperone for Gaucher disease. Compound 5 behaved similarly to NNDNJ, whereas compounds 6, 7, 9, 52, and 55 were significantly more efficient. For example, the recombinant enzyme incubated with 50 mM 6 retained over 40% of the initial activity after 1 h, which is eight-fold higher than the untreated enzyme and about twice as compared with 50 mM NNDNJ-treated enzyme. 32 The protective effect was strongly dose-dependent for the D-gluco configured derivatives bearing the n-octyl substituent (5-7), a feature also observed for NNDNJ, but was almost doseindependent in the 50-150 mM range in the case of the branched derivative 52, the adamantane derivative 55 and, especially, for the bicyclic galactonojirimycin derivative 9. This might reflect that those compounds have already reached the maximum stabilizing activity at 50 mM, about 80% imiglucerase retained activity after 20 min at 48
• C. Although this compares unfavourably with 6 or 7 (about 100 and 90% retained activity at 150 mM M after 20 min, respectively), it should be noted that 9, 52 and 55 are much more efficient at protecting the enzyme over longer period of times (e.g., 60% activity after 60 min in the presence of 50 mM of 9 or 70% after 60 min in the presence of 150 mM of 52; to be compared with only 50% for 6 or NNDNJ after 60 min at 150 mM), 30 which makes them very attractive candidates for further biological studies.
It is worth noting that the ensemble of results above discussed evidences that the inhibitory activity is not necessarily correlated with the enzyme stabilization effect. Thus, compounds 5-7 and 8-10 very similarly inhibited imiglucerase (Tables 1  and 2 ) but behaved quite differently in the thermal-denaturation protection assay, with compounds 8 and 10 being actually inactive.
Conclusions
In summary, a general strategy for the preparation of bicyclic nojirimycin and galactonojirimycin related sp 2 -iminosugars analogues adapted to molecular diversity-oriented schemes has been disclosed and applied to the synthesis of a library of glycomimetics differing in C-4 configuration (D-gluco and D-galacto), the structure of the five-membered ring (cyclic isourea, isothiourea or guanidine) and the nature of the N¢-substituent (apolar, polar, linear or branched). Glycosyl hydrolase inhibition studies evidenced a remarkable influence of the nature of the exocyclic substituent on the potency and selectivity of binding towards a range of commercial glycosidases, although selectivity towards b-glucosidases was generally observed. Amphiphilic derivatives bearing hydrophobic N¢-substituents were much more potent than derivatives bearing polar substituents, which also correlated with potent inhibition of the recombinant human b-glucocerebrosidase (imiglucerase) used in enzyme replacement therapy for Gaucher disease. We have further tested the ability of these compounds to increase imiglucerase stability against thermal denaturation, as an in vitro assessment of their potential as pharmacological chaperones. Analysis of the results in comparison with data for the iminosugar derivative NNDNJ evidenced the higher chaperoning potency of sp 2 -iminosugars and stresses their potential in pharmacological chaperone therapy and combined therapy strategies.
Experimental General methods
Reagents and solvents were purchased from commercial sources and used without further purification. Optical rotations were measured with a JASCO P-2000 polarimeter, using a sodium lamp (l = 589 nm) at 22
• C in 1 cm or 1 dm tubes. IR spectra were recorded on a JASCO FTIR-410 instrument. UV spectra were recorded on Philips PU-8710 instrument, unit for e values: mm -1 cm -1 . NMR experiments were performed at 300 (75.5), 400 (100.6), and 500 (125.7) MHz using Bruker DMX300, DRX400, and DRX500. 1-D TOCSY as well as 2-D COSY and HMQC experiments were carried out to assist in signal assignment. In the FABMS spectra, the primary beam consisted of Xe atoms with maximum energy of 8 keV. The samples were dissolved in m-nitrobenzyl alcohol or thioglycerol as the matrices and the positive ions were separated and accelerated over a potential of 7 keV. NaI was added as cationizing agent. Thinlayer chromatography was performed on E. Merck precoated TLC plates, silica gel 30F-245, with visualization by UV light and by charring with 10% H 2 SO 4 or 0.2% w/v cerium(IV) sulfate-5% ammonium molybdate in 2 M H 2 SO 4 or 0.1% ninhydrin in EtOH. Column chromatography was performed on Chromagel (SDS silica 60 AC.C, 70-200 mm). Elemental analyses were performed at the Servicio de Microanálisis del Instituto de Investigaciones Químicas de Sevilla, Spain. 5-Azido-5-deoxy-1,2-Oisopropylidene-6-O-tetrahydropyranyl-a-D-glucofuranose 11 was prepared from commercial 6,3-D-glucuronolactone following the procedure already reported. 14 2,3,4,6-Tetra-O-acetyl-b-Dglucopyranosyl isothiocyanate (14) was synthesized from the corresponding per O-acetyl glucopyranosyl bromide following the procedure of Camarasa et al. 16 5-Azido-5-deoxy-1,2-di-Oisopropylidene-a-D-galactofuranose 12 was obtained from Dgalactose using the reported route. 15 The cyclic thiourea a-Dglucofuranose derivative 64 was prepared from commercial 6,3-D-glucuronolactone following the procedure already reported.
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The cyclic thiourea a-D-galactofuranose derivative 65 was synthesized from 5-azido-3-O-benzoyl-5-deoxy-a-D-galactofuranose following the reported route.
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General procedure for the inhibition assay against the commercial enzymes
Inhibition constant (K i ) values were determined by spectrophotometrically measuring the residual hydrolytic activities of the glycosidases against the respective o-(for b-glucosidase from bovine liver) or p-nitrophenyl a-or b-D-glycopyranoside (for other glycosidases) or a,a¢-trehalose (for trehalase) in the presence of compounds 37-39, 52-57, 62, 63, and 70-73. Each assay was performed in phosphate buffer or phosphate-citrate buffer (for a-or b-mannosidase and amyloglucosidase) at the optimal pH for the enzymes. The reactions were initiated by addition of enzyme to a solution of the substrate in the absence or presence of various concentrations of inhibitor. The mixture was incubated for 10-30 min at 37
• C or 55 • C (for amyloglucosidase) and the reaction was quenched by addition of 1 M Na 2 CO 3 or a solution of GLC-Trinder (Sigma, for trehalase). Reaction times were appropriate to obtain 10-20% conversion of the substrate in order to achieve linear rates. The absorbance of the resulting mixture was determined at 405 nm or 505 nm (for trehalase). Approximate values of K i were determined using a fixed concentration of substrate (around the K M value for the different glycosidases) and various concentrations of inhibitor. Full K i determinations and enzyme inhibition mode were determined from the slope of Lineweaver-Burk plots and double reciprocal analysis. Representative examples of the Lineweaver-Burk plots, with typical profile for competitive inhibition mode, are shown in the Electronic Supplementary Information. †
Imiglucerase inhibition assay
In vitro activity was determined with 4 mM 4-methylumbelliferylb-D-glucopyranoside in McIlvaine buffer (pH 5.2). Enzyme solutions (25 mL from a stock solution containing 0.1 mg of protein/mL) in the presence of 0.2% (w/v) sodium taurocholate and 0.1% (v/v) TritonX-100 in McIlvaine buffer (pH 5.2) were incubated at 37
• C without (control) or with inhibitor during 30 min, and after addition of corresponding substrate solution (60 mL), incubations were maintained at 37
• C for 10 min. Enzymatic reactions were stopped by the addition of 150 mL of 100 mm glycine/NaOH buffer (pH 10.6). The amount of 4-methylumbelliferone formed was determined with a 1420 VICTOR 2 Multilabel Counter (Wallac) fluorometer at 355 nm (excitation) and 460 nm (emission). IC 50 values were determined by plotting percent activity versus log [I], using at least five different inhibitor concentrations.
Thermal stabilization assay
Following a modification of a reported method, 31 Imiglucerase aliquots (48 mL, 2 mg ml -1 ) were incubated at pH 7.4 with 0 (control), 150, 100, or 150 mm test compound at 48
• C. Subsequently, 150 mL of 0.1 m acetate-phosphate buffer (pH 5.0) and 100 mL of substrate (4 mM 4-methyllumbelliferyl b-D-glucoside) in McIlvaine buffer (pH 5.2) were added at different times and incubated for 10 min at 37
• C, in the presence of 0.l% Triton X-100 and 0.2% taurodeoxycholic acid. Then an amount of 300 mL of glycine/NaOH buffer (100 mM, pH 10.6) was added and liberated 4-methylumbelliferone was measured. Enzyme activity was reported relative to that of the enzyme at 37
• C.
General procedure for the synthesis of 5-thioureido-a-Dglucofuranose derivatives 30-33 and 40-45.
A solution of 5-azido-5-desoxy-1,2-O-isopropylidene-6-O-tetrahydropyranyla-D-glucofuranose 14 11 (300 mg, 0.91 mmol) in MeOH (5 mL) was hydrogenated at atmospheric pressure for 1 h using 10% Pd/C (90 mg) as catalyst. The suspension was filtered through Celite and concentrated. To a solution of the resulting residue in pyridine (6 mL), Et 3 N (0.71 mL, 5.1 mmol, 5.6 eq) and the corresponding isothiocyanate (1.1 mmol, 1.2 eq) were added and the mixture was stirred at room temperature for 18 h. In the case of 30-33 the reaction mixture was cooled at -15
• C, Ac 2 O (3 mL) was added dropwise, and the mixture was further stirred for 5 h. Then, the solvent was removed under reduced pressure and the resulting residue coevaporated several times with toluene. The crude product was dissolved in CH 2 Cl 2 -MeOH (1 : 1, 12 mL) and p-toluenesulfonic acid (50 mg, 0.26 mmol, 0.3 eq) was added. The reaction mixture was stirred for 2 h at room temperature, and then diluted with CH 2 Cl 2 (8 mL), washed with saturated aqueous NaHCO 3 (2 ¥ 8 mL), dried (MgSO 4 ), and concentrated. The resulting residue was purified by column chromatography using the eluent indicated in each case. Acetyl-5-deoxy-1,2-O-isopropylidene-5-[N¢-(2,3,4,6-tetra-O-acetyl-b-D-glycopyranosyl)thioureido]-a-D-glucofuranose (31) . 
3-O-
Online 2 H, CH 2 N), 2.11 (s, 3 H, MeCO), 1.54 (m, 2 H, CH 2 CH 2 N), 1.48
Column chromatography, eluent 1 : 1 → 2 : 1 EtOAc-petroleum ether.
3-O-Acetyl-5-deoxy-1,2-O-isopropylidene-5-(N¢-phenylthioureido)-a-D-glucofuranose (32)
.
3-O-Acetyl-5-(N¢-acetyl-N¢-phenylthioureido)-5-deoxy-1,2-Oisopropylidene-a-D-glucofuranose (33).
Column chromatography, eluent 100 : 1 2 H, H-6a, H-6b), 2.07 (s, 3 H, MeCO), 1.92 (s, 3 H, MeCONH) -(N,N -Bis(2-hexanamidoethyl)aminoethyl)thioureido]-5-deoxy-1,2-O-isopropylidene-a-D- Adamantan-1-ylcarbonylamino-3,6,9-trioxaundecyl • C under Ar, methanesulfonic chloride (80 mL, 1.03 mmol, 1.2 eq) was added. The reaction mixture was stirred for 7 h and allowed to warm to 10
5-[N¢
5-[N¢-(8-tert-Butoxycarbonylaminooctyl)thioureido]-5-deoxy-1,2-O-isopropylidene-a-D-glucofuranose (41)
5-[N¢-(4-tert-Butoxycarbonylaminobutyl)thioureido]-5-deoxy-1,2-O-isopropylidene-a-D-glucofuranose (42
5-[N¢-(11-Azido-3,6,9-trioxaundecyl)thioureido]-5-deoxy-1,2-Oisopropylidene-a-D-glucofuranose (44)
5-[N¢-(11-
• C. Then, ice-water (30 mL) was added and the solution was extracted with CH 2 Cl 2 (3 ¥ 25 mL). The combined extracts were washed with iced saturated aqueous NaHCO 3 (20 mL), dried (MgSO 4 ), and concentrated. In the case of the mixture of thioureido derivatives 32 and 33 the reaction was deacetylated by the Zemplen method. The resulting residue was purified by column chromatography using the eluent indicated in each case. , H-4), 3.76 (ddd, 1 H, H-5¢), 3.53 (dd, 1 H , H-4), 3.78 (bs, 1 H, OH) , 3 .56 (dd, 2-(11-Adamantan-1-ylcarbonylamino-3,6,9-trioxaundecyl)amino-4-[(4¢R)-1¢,2¢-O-isopropylidene-b-L-threofuranos-4¢-yl 
General procedure for the synthesis of 5-N,6-S-(N¢-iminomethylidene)-6-thionojirimycin derivatives 37-39 and 52-57.
To a solution of the corresponding 2-amino-2-thiazoline precursor 34 and 35 (0.39 mmol) in dry MeOH (3.5 mL), methanolic NaMeO (1 m, 0.1 equiv per mol of acetate) was added. The reaction mixture was stirred at room temperature for 30 min, then neutralized with solid CO 2 , and concentrated. The resulting deacetylated product was treated with TFA-H 2 O (9 : 1, 2.4 mL) for 30 min, concentrated under reduced pressure, coevaporated several times with water, neutralized with Amberlite IRA-68 (OH -) ion-exchange resin, and subjected to column chromatography with the eluent indicated in each case to obtain the isothioureas 16 and 17. An analogous TFA-catalyzed reaction starting from 36 afforded the phenyl derivative 18. The corresponding 2-amino-2-thiazoline precursor 46-51 (0.13 mmol), after treatment with TFA-H 2 O (9 : 1, 1 mL) for 30 min at 0
• C followed by concentration under reduced pressure, coevaporation several times with water, neutralization with Amberlite IRA-68 (OH-) ion-exchange resin and column chromatography with the eluent indicated in each case afforded the corresponding isothioureas 52-57. Compounds 53 and 54 were obtained as the corresponding hydrochloride salts by freeze-drying from a solution of hydrochloric acid (pH 5). 76 (d, 1 H, J 1,2 = 4.0 Hz, H-1 12 (350 mg, 1.43 mmol) in MeOH (7 mL) was hydrogenated at atmospheric pressure for 1 h using 10% Pd/C (123 mg) as catalyst. The suspension was filtered through Celite and concentrated. The resulting residue was dissolved in pyridine (8 mL), Et 3 N (0.96 mL, 6.9 mmol, 5.6 eq) and the corresponding isothiocyanate (1.5 mmol, 1.2 eq) were added and the mixture was stirred at room temperature for 18 h. Then, the solvent was removed under reduced pressure and the resulting residue coevaporated several times with toluene and purified by column chromatography using the eluent indicated in each case. 
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